Education
About Us
Working with TipRanks
Follow Us
Biohaven Ltd. (BHVN)
NYSE:BHVN
BHVN Stock Chart & Stats
$9.91
-$0.59(-1.49%)
At close: 4:00 PM EST
$9.91
-$0.59(-1.49%)
Day’s Range― - ―
52-Week Range$7.48 - $31.18
Previous CloseN/A
Volume146.24K
Average Volume (3M)2.24M
Market Cap
$1.49B
Enterprise Value$1.06B
Total Cash (Recent Filing)$319.14M
Total Debt (Recent Filing)$278.86M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
May 08, 2026EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.21
Shares Outstanding150,417,080
10 Day Avg. Volume2,657,724
30 Day Avg. Volume2,241,406
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)23.33
Price to Sales (P/S)0.00
P/FCF Ratio-1.99
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-514.81
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
$20.44Price Target Upside106.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Tolerability And AdoptionEarly signals that opakalim may match competitor seizure reduction while producing fewer central nervous system side effects could permit promotion based on tolerability and encourage clinician uptake among patients sensitive to neurologic adverse effects.
IgA Nephropathy Therapeutic PotentialBHV-1400's ability to target disease-specific IgA while sparing normal immunoglobulins, together with rapid proof-of-concept responses, supports its potential to become a chronic, best-in-class therapy for IgA nephropathy.
Mechanism ValidationRobust positive results for a competing Kv7 activator support Kv7 channel activation as a valid approach and increase confidence that opakalim can meaningfully reduce seizures, reinforcing the program's scientific rationale.
Bears Say
Capital Allocation And Pipeline RiskR&D spending reductions and pipeline reprioritization to preserve capital increase the likelihood of program trims or additional fundraising, which could pressure progress and investor sentiment if development momentum slows.
Competitive PositioningBeing second to market behind a confirmed Kv7 activator may constrain opakalim's initial market share and limit commercial upside despite any tolerability differentiation.
Data Credibility And Disclosure RiskLimited patient-level detail, unusually low reported safety rates in open-label data, and absence of key endpoints raise uncertainty about the credibility and translatability of reported opakalim efficacy ahead of placebo-controlled trials.
Biohaven Ltd. News
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $7.48 and its highest was $31.18 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $1.49B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is May 08, 2026 which is in 55 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Mar 02, 2026. The company reported -$1.21 earnings per share for the quarter, missing the consensus estimate of -$1.188 by -$0.022.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -0.86.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 150,417,080 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$1.21 in its last earnings report, missing expectations of -$1.188. Following the earnings report the stock price went down -9.653%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biohaven Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.44 (106.26% Upside)
$20.44 (106.26% Upside)
Blogger Sentiment
Bearish
BHVN Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Very Bullish
Bullish news 89%
Bearish news 11%
Bearish news 11%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.30%
12-Months-Change
Fundamentals
Return on Equity
-688.89%
Trailing 12-Months
Asset Growth
-26.61%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
BHVN Stock 12 Month Forecast
Average Price Target
$20.44
▲(106.26% Upside)
Technical Analysis
Ownership Overview
11.15% Insiders
10.68% Mutual Funds
6.84% Other Institutional Investors
62.22% Public Companies and
Individual Investors